Hyaluronic Acid Fillers
Hyaluronic acid (HA) filler is a useful material category, but it is not a complete product description. Finished gels can differ in HA concentration, crosslinking and manufacturing process, gel architecture, added uncross-linked HA, lidocaine, syringe presentation, labeled indication, and regional identity.
Those differences should be established from the exact product and market before a formulation or clinical claim is transferred across a family.
What belongs in this reference area
Section titled “What belongs in this reference area”The initial scope is professionally administered injectable HA soft-tissue fillers used for aesthetic correction or augmentation.
| Product context | Initial treatment in this index | Why the boundary matters |
|---|---|---|
| Cross-linked HA soft-tissue filler | Included | The finished gel, exact variant, and local label define the reference entry |
| Injectable marketed for hydration or skin quality, whether cross-linked or not | Not automatically included | Skin booster is not a sufficiently precise substitute for formulation, indication, or regulatory identity |
| PDLLA + HA or another material–HA hybrid | Kept with the material that changes the product system | The HA component does not make the entire product an HA-only filler |
| Intra-articular, ophthalmic, topical, or oral HA | Excluded | These products have different intended uses, presentations, and evidence |
| Needle-free or unverified bulk gel | Excluded | The FDA has not approved needle-free devices for filler injection and warns against unapproved filler products (FDA dermal-filler information 🔗) |
This is an editorial scope boundary, not a claim that every market uses the same regulatory vocabulary.
Read the finished gel, not the ingredient alone
Section titled “Read the finished gel, not the ingredient alone”| Layer | Question to verify | What it does not establish by itself |
|---|---|---|
| HA identity | What HA source or raw-material description is documented? | Crosslinking, gel structure, or clinical behavior |
| Formulation | What concentration, crosslinker, excipients, and lidocaine are stated? | Equivalent performance to another product with the same concentration |
| Gel architecture | How does the exact source describe the network, sizing, or manufacturing technology? | A universal monophasic or biphasic class |
| Physical measurements | Under what method were G′, cohesivity, swelling, or extrusion force measured? | A guaranteed result in a specific anatomy |
| Finished presentation | Which syringe, volume, supplied tool, storage condition, and single-use instruction apply? | Permission to substitute another regional presentation |
| Label and evidence | Which indication, placement, age range, and follow-up endpoint were studied or approved? | Approval for common off-label use |
The FDA describes HA as an absorbable filler material that may be chemically modified through crosslinking and directs readers to product-specific approvals and labeling. It also notes that approved indications vary by exact filler (FDA-approved dermal fillers 🔗; FDA dermal-filler information 🔗).
The first reading path
Section titled “The first reading path”The first two foundation pages establish how later product entries will be interpreted.
| Start with | Practical question |
|---|---|
| Formulation and gel architecture | Which formulation fields identify the finished product, and which familiar labels can mislead? |
| Rheology and physical properties | What do common laboratory measurements describe, and when are product comparisons valid? |
Product family map
Section titled “Product family map”These first family entries apply the same reading rules to four different formulation and documentation systems.
| Family | First US reference question |
|---|---|
| Restylane | Which distinctions belong to NASHA and XpresHAn/OBT products, and which remain exact-variant questions? |
| Juvéderm | How do Hylacross and Vycross names relate to exact formulation, presentation, and indication? |
| Belotero | Which products and indications currently sit inside the US family, and where does non-US naming diverge? |
| Teoxane RHA | How do anesthetic, commercial naming, PNT terminology, and product-specific placement differ across the collection? |
The family set is a documentation and formulation map, not a market ranking or a claim that one technology predicts clinical superiority.
Family names are not global formulation identifiers
Section titled “Family names are not global formulation identifiers”A family can contain multiple products intended for different labeled uses, and a familiar name can represent different variants across markets. Record at least:
- exact product name and variant
- country or regulatory market
- label, IFU, or approval-record date
- HA concentration, lidocaine, and syringe presentation
- approved indication and placement wording
- developer, manufacturer, approval holder, owner, and commercial company where those roles differ
For example, the FDA describes Restylane Defyne as a cross-linked bacterial-source HA gel at 20 mg/mL with 3 mg/mL lidocaine, while the US physician labeling describes Belotero Balance (+) as a bacterially fermented, BDDE-cross-linked HA gel at 22.5 mg/mL with 0.3% lidocaine in a prefilled syringe. These facts identify two exact US products; the concentrations do not rank their clinical behavior (FDA Restylane Defyne approval 🔗; FDA Belotero Balance (+) labeling 🔗).
Reversibility needs a product and event context
Section titled “Reversibility needs a product and event context”Hyaluronidase can degrade many HA gels, but reversible should not be treated as a promise of complete, immediate, or uniform removal. In-vitro studies have found time-, dose-, and product-dependent differences in degradation; their experimental results do not by themselves define an in-vivo protocol (time- and dose-dependent degradation study 🔗; standardized in-vitro degradation study 🔗).
Elective correction of an aesthetic result, a suspected vascular event, infection, and an inflammatory presentation are different clinical problems. Hyaluronidase does not replace product verification, anatomy knowledge, early event recognition, or an established emergency pathway.
Connection with collagen stimulators
Section titled “Connection with collagen stimulators”The Collagen Stimulators area organizes products first by material and physical form. This HA area organizes them first by finished-gel formulation and product family.
Juvelook remains in the collagen-stimulator graph because its PDLLA + HA composition is not equivalent to an HA-only filler. The immediate-versus-delayed framework also helps separate the immediate presence of an HA gel from the different time course of a reconstituted or particle-based product.